Full View

High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

M Edwyn Harrison - Alimentary pharmacology & therapeutics, 2011 - Wiley Online Library
Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid
(UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of …
被引用次数：101 相关文章

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the
likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To …

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - asu.elsevierpure.com
Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the
likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To …

[引用][C] High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - cir.nii.ac.jp
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage
primary sclerosing cholangitis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - search.ebscohost.com
Abstract Aliment Pharmacol Ther 2011; 34: 1185-1192 Summary Background
Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of …
[HTML] nih.gov

[HTML][HTML] High dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - ncbi.nlm.nih.gov
Background Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the
likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim Our …
[PDF] academia.edu

[PDF][PDF] High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard… - Aliment Pharmacol …, 2011 - academia.edu
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early
stage primary sclerosing cholangitis Page 1 High-dose ursodeoxycholic acid increases risk of …

High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH Imam, E Sinakos, AA Gossard, KV Kowdley… - Alimentary …, 2011 - infona.pl
Aliment Pharmacol Ther 2011; 34: 1185–1192 Summary Background Ursodeoxycholic acid
(UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of …

[引用][C] High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

MH IMAM, E SINAKOS, J PETZ… - Alimentary …, 2011 - pascal-francis.inist.fr
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early
stage primary sclerosing cholangitis CNRS Inist Pascal-Francis CNRS Pascal and Francis …

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

MH Imam, E Sinakos, AA Gossard… - Alimentary …, 2011 - europepmc.org
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage
primary sclerosing cholangitis. - Abstract - Europe PMC Sign in | Create an account …